Lowest Price Guaranteed
Pages
245
Last Updated
January 2026
View Count
19343
The radiopharmaceuticals market size is estimated to grow from USD 14.2 billion in 2026 to reach USD 31.0 billion in 2032 and USD 54.6 billion by 2040, representing a higher CAGR of 10.1% during the forecast period 2026 to 2040.
To learn more about this report, request a free sample copy
Radiopharmaceuticals, also known as radioactive drugs or radioisotope-conjugated drugs, are radioactive compounds used to diagnose and treat a range of disorders, particularly oncological, cardiovascular, and neurovascular disorders. They deliver radiation directly to specific tissues, enabling precise imaging or treatment of affected areas while minimizing damage to healthy cells.
Over the years, there has been a continued rise in the global burden of cancer, driven by factors such as aging population, changing lifestyles, and increased exposure to environmental risk factors. According to the American Cancer Society, the US expects over 2 million new cancer cases alone. This growing incidence is driving demand for more innovative and effective treatment options.
 |
 |
 |
In this context, radiopharmaceuticals have emerged as a potential alternative and are well-positioned to offer targeted solutions for both detecting and treating primary and metastatic cancers, including those resistant to conventional therapies.
Further, considering the ongoing necessity, several industry leaders have accelerated their research on radiopharmaceuticals that can aid in the management of diseases beyond cancer. It is imperative to state that key players have made significant investments in the field of nuclear medicine to drive innovations.
 |
 |
 |
Notably, in June 2024, Jubilant Radiopharma announced an investment of USD 50 million for the expansion of its positron emission tomography (PET) radiopharmaceutical manufacturing facilities. The company also plans to add six new sites on its strategic locations in the US. Recently, in response to the threat of import tariffs from the Trump administration, Novartis announced its plans to invest USD 23 billion in the US. Part of this funding will establish new radiopharmaceutical therapy plants in Florida and Texas and expand existing radioligand therapy manufacturing facilities across the US.
 |
 |
 |
As more drug developers expand their radiopharmaceutical capabilities and portfolios, we believe that the radiopharmaceuticals market will experience robust growth, offering significant opportunities for stakeholders in the coming years.
| Key Report Attributes | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2040 | |
| Market Size 2026 | $14.2 Billion | |
| Market Size 2040 | $54.6 Billion | |
| CAGR | 10.1% | |
The market analysis also features the likely distribution of the current and forecasted opportunity within the radiopharmaceutical domain across various segments, such as purpose of radiopharmaceutical, type of diagnostic radiopharmaceutical, type of emitter, type of radioisotope, therapeutic area, end users, key geographical regions and leading players.
We have created three radiopharmaceuticals market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.
Several recent developments have taken place in the field of radiopharmaceuticals, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall radiopharmaceuticals market trends detailed in our analysis.
The market research report presents an in-depth analysis of the various radiopharmaceutical companies, across different segments, as defined in the table below:
| Market Segmentations | Details | |
| Purpose of Radiopharmaceutical |
|
|
| Type of Diagnostic Radiopharmaceutical |
|
|
| Type of Emitter |
|
|
| Type of Radioisotope |
|
|
| Therapeutic Area |
|
|
| End Users |
|
|
| Geographical Regions |
|
|
| Market in North America |
|
|
| Market in Europe |
|
|
| Market in Asia-Pacific |
|
|
| Market in Middle East and North Africa |
|
|
| Market in Latin America |
|
|
Advancements in nuclear medicine, supportive regulatory frameworks, and the rising demand for personalized treatment approaches have accelerated the development of radiopharmaceuticals, strengthening their role in precision healthcare. Innovations in imaging technologies, strategic collaborations, and a robust pipeline of next generation radioligand therapies continue to broaden their clinical applications and enhance treatment outcomes across oncology and beyond.
As the global market for radiopharmaceuticals expands, the demand for innovative drug development and manufacturing capabilities is rising rapidly. Interestingly, the number of clinical trials evaluating radiopharmaceuticals grew by 37% between 2020-2024. For drug developers, effectively navigating evolving regulatory requirements and investing in advanced technologies are crucial to capitalize on these opportunities.
Anders Månsson, (CEO, Oncoinvent), states, “There is no question about the fact that radiopharmaceuticals has emerged as perhaps the “hottest” space in oncology right now with a substantial interest from professional investors, and also with some Big Pharma acquisition activity. Development in the area has matured, development results are very promising, and the few radiopharmaceuticals that have already made it to market have demonstrated the ability to live up to promises of a high commercial potential.”
| Report Deliverables | Details | |
| Excel Data Packs (Complimentary) |
|
|
| Key Radiopharmaceutical Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
The “Radiopharmaceuticals Market: Industry Trends and Global Forecasts, till 2040” market report features an extensive study of the current market landscape of approved as well as clinical and preclinical radiopharmaceuticals, partnerships and collaborations, clinical trial analysis, ongoing megatrends analysis, supply chain analysis, regulatory landscape, market impact analysis and market size and future opportunities within the radiopharmaceutical industry, during the forecast period.
The current market landscape includes over 120 approved radiopharmaceuticals for different therapeutic and diagnostic purposes. Of these, most drugs use Technetium-99m and Fluorine-18 radioisotopes to diagnose various diseases. The majority (55%) of the approved diagnostic radiopharmaceuticals are used in SPECT imaging, where most radioactive tracers emit gamma radiation to create 3D images of organ function and blood flow.
Besides the above trends, most radiopharmaceuticals treat oncological disorders (particularly prostate cancer) and are administered intravenously. Over 90% of the drugs are available in liquid dosage form. Further, it is imperative to state that more than 30 drug developers are actively engaged in the development of approved radiopharmaceuticals across different geographical regions, with most developers being large and very large players.
Over 410 radiopharmaceuticals are currently under investigation across different stages of development for treating various disorders, particularly cancer therapeutics. Of these, close to 30% are alpha emitters. Majority (65%) of the drugs in the development pipeline target therapeutic purposes. Currently, researchers are evaluating most radiopharmaceuticals with antibodies and peptide therapeutics as carrier molecules.
Around 85 developers are actively exploring and investigating various radiolabeled compounds to develop effective diagnostic and therapeutic radiopharmaceuticals. Notably, over 80% of these players are small and mid-sized firms; of these, close to 50% developers are headquartered in North America.
The global radiopharmaceuticals market size is likely to be worth $ 14.2 billion in 2026 and will reach $ 54.6 billion by 2040. In terms of the purpose of radiopharmaceuticals, diagnostic radiopharmaceuticals segment holds the largest share of the radiopharmaceuticals market. On the contrary, the market size for therapeutic radiopharmaceuticals is likely to grow at a relatively higher CAGR of 13.3% during the forecast period.
Several factors drive the growth of this market such as rising prevalence of oncological and cardiovascular disorders, advancements in imaging technologies, and increased investments in nuclear medicine research. In addition, the shift towards personalized medicine or tailored diagnostic and therapeutic solutions is accelerating innovation and development in this field.
Clinical trials are investigating various therapeutic and diagnostic radiopharmaceuticals across several geographical regions including North America, Europe, Asia-Pacific and MENA. Notably, North America accounts for 48% of the clinical trials registered in this domain, followed by Europe. Recently, researchers have gained momentum in exploring radiopharmaceuticals for targeting various disorders, particularly prostate cancer, which has drawn attention from several industry players to conduct trials in this domain.
North American companies are likely to dominate the global radiopharmaceuticals market in 2040, with over 45% of radioactive drug developers based in the region. Growing demand for targeted radiotherapies and the region’s strong healthcare infrastructure is driving this dominance.
In fact, several diagnostic and therapeutic radiopharmaceuticals are likely to receive approval in the US market in the current year. Isotope Technologies Munich (ITM) plans to file for US New Drug Application (NDA) submission for ITM-11 (177Lu-edotreotide) in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The submission is planned for 2025. In addition, Telix Pharmaceuticals expects to launch three diagnostic radiopharmaceuticals in the US market, namely Gozellix (TLX007-CDx) for PSMA imaging of prostate cancer, Pixclara (TLX101-CDx) for glioblastoma imaging, and Zircaix (TLX250-CDx) for kidney cancer imaging.
The market in Asia-Pacific is expected to grow at a relatively high CAGR (12.0%), during the forecast period till 2040. Several factors drive this growth, including increasing healthcare investments, a growing geriatric population, rising prevalence of cancer, and expanding access to advanced diagnostic and therapeutic technologies in the region.
Japan is leading the way in the Asia-Pacific market with several companies actively developing and producing radiopharmaceuticals. In March 2025, National Cancer Center Japan and PeptiDream announced positive results for a first-in-human trials for PD-32766 as a PET diagnostic for renal cell carcinoma.
Other big pharmaceutical companies are also taking strategic initiatives to gain a foothold in the Japanese market. In December 2024, GE Healthcare announced that it has completely acquired Nihon Medi-Physics, a diagnostic radiopharmaceutical manufacturer.
The increasing prevalence of chronic diseases, coupled with ongoing technological advancements in nuclear medicine, drives the market for radiopharmaceuticals, positioning it for steady growth in the foreseeable future. Additionally, increased funding activity and increased support from governments, for instance, the U.S. Department of Energy supporting radionuclide production, while the IAEA promoting global access to radiopharmaceuticals, is fostering further innovation.
The rising demand for radiopharmaceuticals is also creating opportunities for radiopharmaceutical manufacturing companies, where a number of players have announced capacity expansions at existing facilities or setting up of new facilities. Government funded programs are also helping set up nuclear reactors and cyclotron facilities for manufacturing of radioisotopes.
It is worth mentioning that increasing preference for personalized medicine, strategic alliances and rapid healthcare infrastructure development in regions like Asia-Pacific is opening new market avenues for radiopharmaceuticals.
To strengthen their market position in this rapidly evolving industry, key players like Lantheus, Curium, Novartis and BMS are emphasizing strategic acquisitions, collaborations and partnerships to enhance their radiopharmaceutical portfolios. For instance, in April 2025, Lantheus completed the acquisition of Evergreen Theragnostics for $1 billion and Curium acquired Nucleis.
Interestingly, in 2024, several blockbuster acquisitions took place, such as BMS acquiring RayzeBio for $4.1 billion, AstraZeneca purchasing Fusion Pharmaceuticals for $2.4 billion, and Eli Lilly acquiring Point Biopharma for $1.4 billion. These deals reflect the surging momentum in the sector.
It is worth highlighting that, majority of the deals signed in this domain focus on therapeutic radiopharmaceuticals, targeting oncological disorders. Drug developers’ persistent efforts to advance their radiopharmaceutical pipeline is driving rapid market expansion in this domain.
Technological advancements in the radiopharmaceutical industry are revolutionizing both production and clinical applications. Novel radioligand therapies (including alpha therapies) and advanced labeling strategies enable more precise targeting and reduce side effects.
The integration of artificial intelligence into radiopharmaceutical software accelerates drug design and validation, while cutting-edge imaging technologies like PET and SPECT are improving diagnostic accuracy. These advancements are reducing diagnostic errors as well as improving patient outcomes, leading to the growing adoption of radiopharmaceuticals in the healthcare sector.
The emergence of theranostics (integrating diagnosis and treatment capabilities) represent a significant advancement in modern medicine. “The most exciting development in theranostics is the use of a type of radioactivity called alpha emitters that are 100 times more powerful.” (Jason Lewis, Chief of MSK’s Radiochemistry and Imaging Sciences Service and the Emily Tow Jackson Chair).
This dual approach reduces the need for multiple procedures and ultimately lowers the overall treatment costs. Notably, researchers have accelerated the study of theranostics beyond oncology, with numerous clinical trials registered for cardiovascular, neurological, and infectious diseases.
Further, the success of Pluvicto (a theranostic by Novartis) has significantly boosted the radiopharmaceutical theranostics market, generating USD 1.4 billion sales in 2024 alone.
The radiopharmaceutical supply chain faces critical challenges because nuclear reactors and cyclotrons, which are essential for producing radioisotopes, are limited worldwide. The short half-lives of radioisotopes complicate inventory storage and require precise "just-in-time" delivery, which can lead to wasted doses and disrupted patient care.
In addition to the above challenge, mandatory facility downtimes, high costs of specialized infrastructure, the need for skilled personnel, and evolving regulatory requirements frequently cause isotope shortages. These challenges significantly impact the market’s ability to meet growing demand and maintain consistent patient care.
Recently, the diagnostic industry experienced a shortage of Tc-99m due to pipe deformation repair work at a high-flux reactor in Petten, Netherlands, operated by the Nuclear Research and Consultancy Group. The reactor supplies Molybdenum-99 to the technetium generators. The facility had earlier been closed for six months for repair work in 2009.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the radiopharmaceutical industry, across different geographies. Amongst other elements, the market report includes:
Radiopharmaceuticals are rapidly transforming the diagnosis and treatment of chronic diseases, driven by significant investments from major pharmaceutical companies in precision medicine and theranostics. Notably, the introduction of targeted alpha therapies and the exploration of novel targets (such as FAP, CAIX) are expanding their applications beyond oncology. The industry is witnessing robust growth, particularly in North America, which leads in demand, owing to ongoing innovation, strategic partnerships, and higher patient acceptance for nuclear medicine. Further, I believe, alpha emitting radiopharmaceuticals will make a profound impact in the coming years driven by their rising clinical activity and increasing investment in next-generation oncology treatments.
Akarshika has been working as a competent business research analyst since she joined Roots Analysis. Throughout her tenure, Akarshika has actively tracked emerging trends and technologies within the pharmaceutical industry. She has contributed to numerous comprehensive research reports that provide in-depth views on topics such as proteomics market, oligonucleotide synthesis market and green chemistry market.